Amgen To Discuss Data Supporting Biologics License Application For ABP 501, A Biosimilar Candidate To Adalimumab
THOUSAND OAKS, Calif., July 12, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Company will discuss data supporting the ABP 501 Biologics License Application (BLA) with the U.S. Food and Drug Administration ' s (FDA) Arthritis...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news
More News: Arthritis | Drugs & Pharmacology | Food and Drug Administration (FDA) | Humira | New Drug Applications | Rheumatology